Specialty Pharmacy

Unexplained drug cost increases are the epicenter of some of the most polemic conversations in US health policy today.

Cosentyx was previously approved for the treatment of moderate-to-severe plaque psoriasis.

Controversial proposal would essentially replace health care plans Americans currently obtain via their employers or purchased individually.

Few state minor-consent laws authorize participation in clinical trials and therapies.

Pricing Sovaldi based on the predicted benefits of therapy in specific hepatitis C patient groups could ultimately lead to greater access for patients.

Large geographic disparities exist in the likelihood of either being removed from the transplant list due to progressive disease or actually receiving a transplant.

Process attaches disease-related protein fragments to spleen cells to prevent MS.

Predictors of higher cost include older age, male sex, and hospital location.

Patients with type 2 diabetes have about a 60% greater risk for developing dementia than their non-diabetic counterparts.

Research examines long non-coding RNAs as biomarkers and therapeutic targets.

Top news of the week in cancer drug development and research.

PKN proteins are gaining recognition as drug targets for cancer research.

Catch up with the latest developments across the health care landscape and sign up for key upcoming conferences.

Tumor depth associated with the highest risk risk ratio of local recurrence.

Government announces plans to increase funding for cancer treatment research and development.

Multi-ingredient capsule funnels different ingredients through 2 parallel inner needles, which could enhance cancer treatment.

Top stories of the week on Specialty Pharmacy Times.

Pair of daily ribavirin-free oral drugs will be analyzed in patients with hepatitis C genotypes 1-6.

A proposal to reduce Medicare Part B payment rates for hospitals participating in the 340B Drug Pricing Program has been approved 14-3 by the Medicare Payment Advisory Commission.

Consistent PrEP use can lower the risk of HIV infection by 92% among those at high risk for transmission.

Many patients with diabetes have high levels of mental illness, multiple comorbidities, and unmet needs.

Gilead Sciences Inc has submitted a new drug application to the FDA for tenofovir alafenamide, a once-daily treatment for adults with chronic hepatitis B virus infection.

Several pharmaceutical market trends are likely to affect pharmacists' practice this year.

Several factors influence survival among patients with both HIV and Hodgkin’s lymphoma.

Discovery can help predict progression to metastatic cancer.

Sarilumab is a human monoclonal antibody that targets the IL-6 receptor.

Test can better analyze the potential disease progression of skin cancer.

B cells can contribute to abnormal immune responses in MS patients.